Avishay Sella

Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial

Thomas Powles, Tibor Csőszi, Mustafa Özgüroğlu et al. · The Lancet Oncology · 2021 · 648 citations · Full text

Medicine, Oncology, Pharmacology +11

Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017

Silke Gillessen, Gerhardt Attard, Tomasz M. Beer et al. · European Urology · 2017 · 643 citations · Full text

Medicine, Oncology, Urology +17

A prospective randomized trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumors.

C. Logothetis, F. H. Dexeus, Laura Finn et al. · Journal of Clinical Oncology · 1990 · 616 citations

Medicine, Oncology, Pharmacology +15

Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial

Michiel S. van der Heijden, Matthew D. Galsky, Yohann Loriot et al. · The Lancet Oncology · 2020 · 498 citations · Full text

Medicine, Oncology, Pharmacology +14

Cabozantinib in Patients With Advanced Prostate Cancer: Results of a Phase II Randomized Discontinuation Trial

David C. Smith, Matthew R. Smith, Christopher J. Sweeney et al. · Journal of Clinical Oncology · 2012 · 443 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +13